Faisal Khurshid
Stock Analyst at Leerink Partners
(4.48)
# 288
Out of 5,124 analysts
29
Total ratings
56.52%
Success rate
33.25%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $70 → $118 | $77.81 | +51.65% | 3 | Dec 9, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $13 → $16 | $12.52 | +27.80% | 2 | Nov 20, 2025 | |
| ABCL AbCellera Biologics | Downgrades: Market Perform | $4 | $3.42 | +16.96% | 2 | Nov 7, 2025 | |
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $32.68 | +22.40% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $11.43 | +74.98% | 1 | Sep 25, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $87.34 | -16.42% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $3.65 | -45.21% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $107.04 | -4.71% | 2 | Jul 10, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $3.37 | -70.33% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $32.76 | +37.36% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $18.97 | -15.66% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.22 | +63.93% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.78 | +1,943.16% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $78.94 | +1.34% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $5.24 | +186.26% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.10 | +163.16% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.32 | +430.30% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.67 | +41.09% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.53 | +836.86% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $5.84 | +88.36% | 1 | Mar 21, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $70 → $118
Current: $77.81
Upside: +51.65%
Trevi Therapeutics
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $12.52
Upside: +27.80%
AbCellera Biologics
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.42
Upside: +16.96%
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $32.68
Upside: +22.40%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $11.43
Upside: +74.98%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $87.34
Upside: -16.42%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $3.65
Upside: -45.21%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $107.04
Upside: -4.71%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $3.37
Upside: -70.33%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $32.76
Upside: +37.36%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $18.97
Upside: -15.66%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.22
Upside: +63.93%
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $0.78
Upside: +1,943.16%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $78.94
Upside: +1.34%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $5.24
Upside: +186.26%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.10
Upside: +163.16%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.32
Upside: +430.30%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.67
Upside: +41.09%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.53
Upside: +836.86%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $5.84
Upside: +88.36%